Sunitinib Malate Capsule
Product Images NDC 82293-017

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Sunitinib Malate (NDC 82293-017). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novugen Pharma (usa) Llc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (Figure0001)

A Kaplan-Meier survival curve showing time to tumor progression probability (%) over weeks for two groups: Sunitinib Malate and placebo. The black line represents Sunitinib Malate with median progression time of 27.3 weeks; the gray line represents placebo with median progression of 6.4 weeks. The graph includes statistical data like hazard ratio and p-value.*

FDA Label Image

Image Description (Figure03)

Kaplan-Meier survival curve comparing disease-free survival probability over time (years) between patients treated with Sunitinib Malate and a placebo. The solid line represents Sunitinib Malate (N=309) with a median survival of 6.8 years, while the dotted line represents placebo (N=306) with a median of 5.6 years. Number of subjects at risk is shown below the x-axis.*

FDA Label Image

Image Description (Figure2)

A survival curve chart comparing progression-free survival probabilities over time in weeks for Sunitinib Malate (N=375) and IFN-α (N=375). The chart shows higher progression-free survival for Sunitinib Malate with a median of 47.3 weeks versus 22.0 weeks for IFN-α. A hazard ratio of 0.42 with 95% confidence interval (0.32, 0.54) and p-value <0.000001 is noted. Number of subjects at risk is listed below the x-axis at specified time points.*

FDA Label Image

Image Description (Figure4)

A Kaplan-Meier survival curve chart comparing progression-free survival probability over time in months for Sunitinib Malate versus placebo. The solid line represents Sunitinib Malate (n=86) with a median survival of 10.2 months, and the dashed line represents placebo (n=85) with a median survival of 5.4 months. The chart includes hazard ratio, confidence interval, and p-value statistics, and displays the number of subjects at risk at various time points.*

FDA Label Image

Image Description (Image001)

Label for Sunitinib Malate Capsules 12.5 mg by Novugen Pharma (USA) LLC. The label specifies 28 capsules per container, includes storage instructions, dosage information, and warnings to keep out of reach of children. It features a barcode, 2D barcode placement, and states the product is made in India.*

FDA Label Image

Image Description (Image002)

Label for Sunitinib Malate Capsules 25 mg by Novugen Pharma (USA) LLC. The label indicates storage instructions, dispensing guidance for 28 capsules, and includes a barcode, lot, serial, and expiration placeholders. The label states the product is for prescription use and made in India.*

FDA Label Image

Image Description (Image003)

Sunitinib Malate Capsules 37.5 mg oral capsules label from Novugen Pharma (USA) LLC. The label shows the dosage strength, quantity of 28 capsules, storage instructions between 20°C to 25°C, and warnings to keep out of children's reach. It includes a barcode and distributor information noting manufacturing in India.*

FDA Label Image

Image Description (Image04)

Label for Sunitinib Malate Capsules 50 mg, oral dosage form by Novugen Pharma (USA) LLC. The label indicates packaging of 28 capsules with storage instructions and a barcode. It includes a note to dispense the medication guide, along with lot and expiration placeholders in an unvarnished area.*

FDA Label Image

Image Description (Structure01)

Chemical structure of Sunitinib Malate showing its molecular framework including aromatic rings, functional groups, and malate salt moiety.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.